CORE ONE LABS INC - CLABF STOCK NEWS

Core One Labs Inc. (OTCQB:CLABF) announced the acquisition of GMP Drug Inc., a privately held company with a GMP facility in Ontario, Canada. This acquisition enables Core One to enhance its operations and provides its subsidiaries, Awakened Biosciences and Vocan Biotechnologies, access to the facility for R&D and production of psychedelic compounds. The GMP facility is licensed to produce Active Pharmaceutical Ingredients, positioning Core One to develop and distribute psychedelic medications more efficiently. The deal, valued at $2.8 million, includes issuing shares to GMP Drug shareholders.

Core One Labs Inc. (OTCQB: CLABF) announced plans for an initial production run of its psilocybin active pharmaceutical ingredient (API) at a GMP facility, scheduled for January 2023. This trial aims to assess commercial production capabilities, paving the way for full-scale manufacturing of high-grade psilocybin. The company anticipates that positive results will attract investors. Increased approval for psilocybin-assisted therapy in Canada and a projected market growth of 13.3% CAGR until 2029 create a favorable environment for Core One’s ambitions in the psychedelic medicine sector.

Core One Labs (OTCQB:CLABF) announced its preparations for potential acquisition opportunities in the psychedelic pharmaceutical sector. Following a previous release from March 2022, the Company's Board of Directors is actively pursuing strategic partnerships. An acquisition could enhance Core One's market presence and competitive advantage while providing access to new capital for innovation in psychedelic compounds. With ongoing advancements through subsidiaries, including patents for psilocybin production, Core One is poised for significant industry attention.

Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF) announced developments through its subsidiary, Akome Biotech Ltd., focused on psychedelic-based drugs for neurological conditions. The company is finalizing funding discussions with Madrid's Universidad Complutense to advance neurogenesis studies that showed promising results. Akome's bioactive compounds have demonstrated significant neurogenetic activity and potential therapeutic effects. The university's funding for further studies is viewed as a positive step in Core One's drug development pipeline.

Core One Labs is advancing towards GMP production of its psychedelic compounds, negotiating with a certified facility to develop affordable psychedelic medicine. This follows Alberta's announcement to regulate psychedelic drugs for therapeutic use starting January 2023. The Company's goal is to manufacture pharmaceutical-grade products for various mental health disorders, including anxiety and depression. Core One has also filed for multiple patents related to psilocybin production and is expanding its operations through medical clinics, positioning itself as a leading player in the emerging psychedelics market.

Core One Labs Inc. announced the development of a proprietary method for isolating and purifying psilocybin from mushroom biomass through its subsidiary, Awakened Biosciences. A patent application has been prepared for submission to the USPTO, potentially allowing them to produce pharma-grade psilocybin. This breakthrough supports Core One's strategy to enter the global psychedelic drugs market, projected to reach US$10.75 billion by 2027. The method may enable partnerships with mushroom producers worldwide, enhancing production capabilities and revenue generation opportunities.

Core One Labs Inc. (OTCQB:CLABF) announced a Letter of Intent (LOI) with Medelys Laboratories for the manufacturing of its proprietary psychedelic active pharmaceutical ingredients (APIs). Effective September 21, 2022, this partnership aims to develop GMP-compliant psilocybin products leveraging Core One's proprietary technology. The arrangement is expected to enhance the production capabilities and distribution networks for pharma-grade psychedelics to health professionals under Canada's Special Access Program. Additionally, the market for psilocybin is substantial, with prices ranging from US$7,000 to US$10,000 per gram.

Core One Labs Inc. (OTCQB: CLABF) has reported successful results from Phase 1 pre-clinical studies conducted by its subsidiary Akome Biotech. The studies demonstrated that selected bioactive compounds potentially mitigate neurological deficits in conditions like Major Depressive Disorder, Stroke, Parkinson's Disease, and Alzheimer's Disease. Following these results, they have received interest from the University of Barcelona to advance to Phase 2 studies, focusing on these compounds' therapeutic effects.

Core One Labs Inc. (OTCQB:CLABF) announces significant progress by its subsidiary, Awakened Biosciences, in producing DMT, with a successful synthesis of a precursor. Approximately 25 grams of this precursor can yield around 15 grams of contaminant-free DMT. This advancement positions Core One as a potential leader in the psychedelics market. Additionally, Akome Biotech, another subsidiary, is working on two DMT-based drug formulations aimed at treating ischemic stroke and Parkinson's Disease, addressing pressing global health issues.